Toward the clinical development of synthetic immunity to cancer

• Published in: Immunological reviews Vol. 320; no. 1; pp. 83 - 99
• Main Authors: Garcia, Julie M, Burnett, Cassandra E, Roybal, Kole T
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.11.2023
• Subjects: Antigens; Cancer; Cancer immunotherapy; Cancer therapies; Cell therapy; Chimeric antigen receptors; Immune system; Immunology; Immunotherapy; Solid tumors; Therapy; Translation; Tumors; synthetic biology; immunology; cancer immunotherapy
• ISSN: 0105-2896; 1600-065X
• DOI: 10.1111/imr.13245

Synthetic biology (synbio) tools, such as chimeric antigen receptors (CARs), have been designed to target, activate, and improve immune cell responses to tumors. These therapies have demonstrated an ability to cure patients with blood cancers. However, there are significant challenges to designing, testing, and efficiently translating these complex cell therapies for patients who do not respond or have immune refractory solid tumors. The rapid progress of synbio tools for cell therapy, particularly for cancer immunotherapy, is encouraging but our development process should be tailored to increase translational success. Particularly, next-generation cell therapies should be rooted in basic immunology, tested in more predictive preclinical models, engineered for potency with the right balance of safety, educated by clinical findings, and multi-faceted to combat a range of suppressive mechanisms. Here, we lay out five principles for engineering future cell therapies to increase the probability of clinical impact, and in the context of these principles, we provide an overview of the current state of synbio cell therapy design for cancer. Although these principles are anchored in engineering immune cells for cancer therapy, we posit that they can help guide translational synbio research for broad impact in other disease indications with high unmet need.